Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEODISCO trial of neoadjuvant gemcitabine + cisplatin with perioperative pembrolizumab versus upfront surgery in resectable extrahepatic cholangiocarcinoma
NL-OMON59297Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, cisplatin and pembrolizumab in hilar cholangiocarcinoma (HC) and distal cholangiocarcinoma (dCCA) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Event-free survival. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
hilar cholangiocarcinoma (HC)distal cholangiocarcinoma (dCCA)
Beyond the preview
Go deeper on NL-OMON59297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59297.